Ver todoArtículos CientíficosPublicaciones EASP
Ordenar por fechaOrdenar por nombre
DescendenteAscendente
EnlaceLupaDetalles

Coste-efectividad e impacto presupuestario del tratamiento con evolocumab frente a estatinas y ezetimiba para la hipercolesterolemia en España

Artículos Científicos

Introducción y objetivos Analizar la razón de coste-efectividad y el impacto presupuestario del tratamiento con evolocumab (inhibidor de la PCSK9) para pacientes en prevención secundaria en el Sistema Nacional de Salud español. Métodos Se realizaron, desde la perspectiva del sistema sanitario público, análisis de impacto presupuestario, modelos de árbol de decisión y Markov, basándose en…

EnlaceLupaDetalles

Coste-efectividad e impacto presupuestario del tratamiento con evolocumab frente a estatinas y ezetimiba para la hipercolesterolemia en España

Artículos Científicos

Introducción y objetivos Analizar la razón de coste-efectividad y el impacto presupuestario del tratamiento con evolocumab (inhibidor de la PCSK9) para pacientes en prevención secundaria en el Sistema Nacional de Salud español. Métodos Se realizaron, desde la perspectiva del sistema sanitario público, análisis de impacto presupuestario, modelos de árbol de decisión y Markov, basándose en…

LupaDetalles

Cost–Utility Analysis of a Medication Adherence Management Service Alongside a Cluster Randomized Control Trial in Community Pharmacy

Artículos Científicos

Background: It is necessary to determine the cost utility of adherence interventions in chronic diseases due to humanistic and economic burden of non-adherence. Purpose: To evaluate, alongside a cluster-randomized controlled trial, the cost-utility of a pharmacist-led medication adherence management service (MAMS) compared with usual care in community pharmacies. Materials and Methods: The trial was conducted…

LupaDetalles

Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain

Artículos Científicos, Investigación

Breast cancer is one of the most frequent malignancies. The aim of the article is to analyse the cost-utility ratio and budgetary impact of talazoparib treatment for patients with locally advanced or metastatic gBRCA + breast cancer from the perspective of the Spanish National Health System. Analyses were based on the EMBRACA clinical trial and the model was constructed…

LupaDetalles

Cost-Utility Analysis of Left Bundle Branch Area Versus Biventricular Pacing for Cardiac Resynchronization Therapy: A Multicenter, Prospective, Quasi-Experimental Study

Artículos Científicos, Investigación, Mujeres EASP

Introduction Cardiac resynchronization therapy (CRT) is a well-established treatment for patients with heart failure (HF). Recently, left bundle branch area pacing (LBBAP) has emerged as a more physiological alternative to biventricular pacing (BVP) for CRT. This study aimed to evaluate the cost-utility of LBBAP CRT compared with BVP CRT. Methods A cost-utility, non-randomized, prospective, multicenter,…

LupaDetalles

Cost-utility analysis of benzodiazepine deprescription in primary care: a cohort study

Artículos Científicos, Mujeres EASP

Background Long-term benzodiazepine (BZD) use is associated with adverse clinical outcomes and increased healthcare utilization. Although deprescription programs aim to reduce these risks, the net economic impact of BZD discontinuation—particularly in terms of healthcare resource use—remains unclear. This study aimed to evaluate the cost-utility of BZD deprescription intervention in primary care, assessing its impact on…

LupaDetalles

Cost-effectiveness of second- or third-line treatment with tisotumab vedotin for metastatic or recurrent cervical cancer

Artículos Científicos, Investigación

Objective To evaluate the cost-effectiveness of tisotumab vedotin (TV) versus single-agent chemotherapy in recurrent or metastatic cervical cancer (r/mCC) after failure of first-line treatment, from the perspective of the Spanish National Health System. Methods Cost-utility analysis was conducted using a partitioned survival model with three health states, over a 60-month time horizon. Efficacy data ‒overall…

LupaDetalles

Cost-Effectiveness of Sacituzumab Govitecan and Physician’s Choice of Treatment in Patients with Metastatic Triple Negative Breast Cancer in Spain

Artículos Científicos, Investigación

Background and Objectives Patients with metastatic triple-negative breast cancer (mTNBC) have poor prognosis and survival outcomes. Sacituzumab govitecan (SG) has shown significant survival benefits, but its cost-effectiveness still needs evaluation. The present study aimed to evaluate the cost-effectiveness of SG versus physician’s choice of treatment in patients with mTNBC in the context of the Spanish…

EnlaceLupaDetalles

Cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant of hematopoietic progenitor cells

Artículos Científicos

The objective of this article is to analyze the ratio of cost-effectiveness and budgetary impact of lenalidomide treatment in patients with multiple myeloma who have undergone autologous transplant in Spain. The analyses were based on clinical trials CALGB 100104 and IFM 2005-02, from the perspective of the National Health System. The alternatives compared were the…